nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprostadil—Azelaic Acid—SRD5A2—uterine cancer	0.0205	0.822	CrCbGaD
Alprostadil—PTGIR—artery—uterine cancer	0.0192	0.055	CbGeAlD
Alprostadil—PTGER2—myometrium—uterine cancer	0.0159	0.0453	CbGeAlD
Alprostadil—PTGER2—uterine cervix—uterine cancer	0.0123	0.0353	CbGeAlD
Alprostadil—PTGER2—decidua—uterine cancer	0.0118	0.0336	CbGeAlD
Alprostadil—PTGER2—endometrium—uterine cancer	0.0112	0.0319	CbGeAlD
Alprostadil—PTGER1—renal system—uterine cancer	0.0109	0.0313	CbGeAlD
Alprostadil—PTGER2—mammalian vulva—uterine cancer	0.0108	0.0309	CbGeAlD
Alprostadil—PTGER2—uterus—uterine cancer	0.0103	0.0294	CbGeAlD
Alprostadil—PTGER2—female reproductive system—uterine cancer	0.00925	0.0264	CbGeAlD
Alprostadil—PTGER1—female reproductive system—uterine cancer	0.00877	0.0251	CbGeAlD
Alprostadil—PTGER2—female gonad—uterine cancer	0.00842	0.024	CbGeAlD
Alprostadil—PTGER2—vagina—uterine cancer	0.00837	0.0239	CbGeAlD
Alprostadil—SLCO3A1—myometrium—uterine cancer	0.0082	0.0234	CbGeAlD
Alprostadil—SLCO2A1—myometrium—uterine cancer	0.00812	0.0232	CbGeAlD
Alprostadil—PTGER1—female gonad—uterine cancer	0.00798	0.0228	CbGeAlD
Alprostadil—PTGIR—epithelium—uterine cancer	0.00729	0.0208	CbGeAlD
Alprostadil—PTGIR—smooth muscle tissue—uterine cancer	0.00703	0.0201	CbGeAlD
Alprostadil—PTGIR—renal system—uterine cancer	0.00676	0.0193	CbGeAlD
Alprostadil—SLCO3A1—uterine cervix—uterine cancer	0.00638	0.0182	CbGeAlD
Alprostadil—SLCO2A1—epithelium—uterine cancer	0.00637	0.0182	CbGeAlD
Alprostadil—SLCO2A1—uterine cervix—uterine cancer	0.00632	0.0181	CbGeAlD
Alprostadil—SLCO2A1—decidua—uterine cancer	0.00602	0.0172	CbGeAlD
Alprostadil—SLCO3A1—renal system—uterine cancer	0.00597	0.0171	CbGeAlD
Alprostadil—SLCO2A1—renal system—uterine cancer	0.00591	0.0169	CbGeAlD
Alprostadil—ABCC5—uterine cervix—uterine cancer	0.00578	0.0165	CbGeAlD
Alprostadil—SLCO2A1—endometrium—uterine cancer	0.00572	0.0163	CbGeAlD
Alprostadil—SLCO3A1—mammalian vulva—uterine cancer	0.00558	0.016	CbGeAlD
Alprostadil—SLCO2A1—mammalian vulva—uterine cancer	0.00553	0.0158	CbGeAlD
Alprostadil—ABCC5—decidua—uterine cancer	0.00551	0.0157	CbGeAlD
Alprostadil—PTGIR—female reproductive system—uterine cancer	0.00542	0.0155	CbGeAlD
Alprostadil—PTGER2—lymph node—uterine cancer	0.00541	0.0155	CbGeAlD
Alprostadil—SLCO2A1—uterus—uterine cancer	0.00527	0.0151	CbGeAlD
Alprostadil—PTGIR—female gonad—uterine cancer	0.00493	0.0141	CbGeAlD
Alprostadil—PTGER2—Prostaglandin Synthesis and Regulation—CYP11A1—uterine cancer	0.00485	0.066	CbGpPWpGaD
Alprostadil—SLCO3A1—female reproductive system—uterine cancer	0.00478	0.0137	CbGeAlD
Alprostadil—SLCO2A1—female reproductive system—uterine cancer	0.00474	0.0135	CbGeAlD
Alprostadil—PTGER2—Ovarian Infertility Genes—MLH1—uterine cancer	0.00447	0.0608	CbGpPWpGaD
Alprostadil—SLCO3A1—female gonad—uterine cancer	0.00435	0.0124	CbGeAlD
Alprostadil—SLCO3A1—vagina—uterine cancer	0.00432	0.0124	CbGeAlD
Alprostadil—SLCO2B1—decidua—uterine cancer	0.00431	0.0123	CbGeAlD
Alprostadil—SLCO2A1—female gonad—uterine cancer	0.00431	0.0123	CbGeAlD
Alprostadil—SLCO2A1—vagina—uterine cancer	0.00428	0.0122	CbGeAlD
Alprostadil—PTGER2—Ovarian Infertility Genes—PGR—uterine cancer	0.00424	0.0577	CbGpPWpGaD
Alprostadil—SLCO2B1—renal system—uterine cancer	0.00423	0.0121	CbGeAlD
Alprostadil—ABCC5—ABC-family proteins mediated transport—ABCC9—uterine cancer	0.00407	0.0554	CbGpPWpGaD
Alprostadil—ABCC5—female gonad—uterine cancer	0.00394	0.0113	CbGeAlD
Alprostadil—ABCC5—vagina—uterine cancer	0.00392	0.0112	CbGeAlD
Alprostadil—SLCO2B1—uterus—uterine cancer	0.00377	0.0108	CbGeAlD
Alprostadil—ABCC4—renal system—uterine cancer	0.00375	0.0107	CbGeAlD
Alprostadil—PTGER2—Ovarian Infertility Genes—ESR2—uterine cancer	0.00373	0.0508	CbGpPWpGaD
Alprostadil—SLCO2B1—female reproductive system—uterine cancer	0.00339	0.00968	CbGeAlD
Alprostadil—PTGER2—Ovarian Infertility Genes—CYP19A1—uterine cancer	0.00339	0.0461	CbGpPWpGaD
Alprostadil—ABCC4—uterus—uterine cancer	0.00334	0.00954	CbGeAlD
Alprostadil—PTGIR—Prostaglandin Synthesis and Regulation—CYP11A1—uterine cancer	0.00328	0.0446	CbGpPWpGaD
Alprostadil—PTGER1—Prostaglandin Synthesis and Regulation—CYP11A1—uterine cancer	0.00328	0.0446	CbGpPWpGaD
Alprostadil—PTGIR—lymph node—uterine cancer	0.00317	0.00905	CbGeAlD
Alprostadil—SLCO2B1—female gonad—uterine cancer	0.00308	0.00881	CbGeAlD
Alprostadil—ABCC4—female reproductive system—uterine cancer	0.003	0.00858	CbGeAlD
Alprostadil—Dinoprostone—CYP11A1—uterine cancer	0.00294	0.118	CrCbGaD
Alprostadil—ABCC5—Fluoropyrimidine Activity—RRM2—uterine cancer	0.00285	0.0388	CbGpPWpGaD
Alprostadil—ABCC4—ABC-family proteins mediated transport—ABCC9—uterine cancer	0.00282	0.0384	CbGpPWpGaD
Alprostadil—SLCO3A1—lymph node—uterine cancer	0.0028	0.00799	CbGeAlD
Alprostadil—PTGER2—Ovarian Infertility Genes—SMAD3—uterine cancer	0.00277	0.0377	CbGpPWpGaD
Alprostadil—SLCO2A1—lymph node—uterine cancer	0.00277	0.00791	CbGeAlD
Alprostadil—ABCC4—female gonad—uterine cancer	0.00273	0.0078	CbGeAlD
Alprostadil—ABCC5—lymph node—uterine cancer	0.00253	0.00724	CbGeAlD
Alprostadil—SLCO2B1—lymph node—uterine cancer	0.00198	0.00567	CbGeAlD
Alprostadil—ABCC4—Fluoropyrimidine Activity—RRM2—uterine cancer	0.00198	0.0269	CbGpPWpGaD
Alprostadil—ABCC4—lymph node—uterine cancer	0.00176	0.00502	CbGeAlD
Alprostadil—PTGER2—Ovarian Infertility Genes—CDKN1B—uterine cancer	0.00154	0.0209	CbGpPWpGaD
Alprostadil—Dinoprostone—CYP19A1—uterine cancer	0.00152	0.0609	CrCbGaD
Alprostadil—ABCC5—Fluoropyrimidine Activity—MTHFR—uterine cancer	0.00144	0.0196	CbGpPWpGaD
Alprostadil—Nervousness—Medroxyprogesterone Acetate—uterine cancer	0.00137	0.00248	CcSEcCtD
Alprostadil—Loss of consciousness—Progesterone—uterine cancer	0.00137	0.00248	CcSEcCtD
Alprostadil—Back pain—Medroxyprogesterone Acetate—uterine cancer	0.00136	0.00247	CcSEcCtD
Alprostadil—Burning sensation—Doxorubicin—uterine cancer	0.00136	0.00246	CcSEcCtD
Alprostadil—Cough—Progesterone—uterine cancer	0.00136	0.00246	CcSEcCtD
Alprostadil—Muscle spasms—Medroxyprogesterone Acetate—uterine cancer	0.00135	0.00246	CcSEcCtD
Alprostadil—Convulsion—Progesterone—uterine cancer	0.00135	0.00244	CcSEcCtD
Alprostadil—Hypertension—Progesterone—uterine cancer	0.00134	0.00243	CcSEcCtD
Alprostadil—Fungal infection—Epirubicin—uterine cancer	0.00132	0.00239	CcSEcCtD
Alprostadil—Discomfort—Progesterone—uterine cancer	0.00131	0.00237	CcSEcCtD
Alprostadil—Anaemia—Medroxyprogesterone Acetate—uterine cancer	0.0013	0.00236	CcSEcCtD
Alprostadil—Feeling hot—Epirubicin—uterine cancer	0.0013	0.00236	CcSEcCtD
Alprostadil—Dry mouth—Progesterone—uterine cancer	0.00129	0.00235	CcSEcCtD
Alprostadil—Oedema—Progesterone—uterine cancer	0.00127	0.0023	CcSEcCtD
Alprostadil—Syncope—Medroxyprogesterone Acetate—uterine cancer	0.00126	0.00229	CcSEcCtD
Alprostadil—Infection—Progesterone—uterine cancer	0.00126	0.00228	CcSEcCtD
Alprostadil—Cardiac arrest—Etoposide—uterine cancer	0.00126	0.00228	CcSEcCtD
Alprostadil—Pharyngitis—Dactinomycin—uterine cancer	0.00125	0.00227	CcSEcCtD
Alprostadil—Injection site pain—Epirubicin—uterine cancer	0.00125	0.00226	CcSEcCtD
Alprostadil—Shock—Progesterone—uterine cancer	0.00125	0.00226	CcSEcCtD
Alprostadil—Tachycardia—Progesterone—uterine cancer	0.00124	0.00224	CcSEcCtD
Alprostadil—Loss of consciousness—Medroxyprogesterone Acetate—uterine cancer	0.00124	0.00224	CcSEcCtD
Alprostadil—Skin disorder—Progesterone—uterine cancer	0.00123	0.00223	CcSEcCtD
Alprostadil—Hyperhidrosis—Progesterone—uterine cancer	0.00123	0.00222	CcSEcCtD
Alprostadil—Fungal infection—Doxorubicin—uterine cancer	0.00122	0.00222	CcSEcCtD
Alprostadil—Convulsion—Medroxyprogesterone Acetate—uterine cancer	0.00122	0.00221	CcSEcCtD
Alprostadil—Feeling hot—Doxorubicin—uterine cancer	0.0012	0.00218	CcSEcCtD
Alprostadil—Hypotension—Progesterone—uterine cancer	0.00119	0.00215	CcSEcCtD
Alprostadil—Discomfort—Medroxyprogesterone Acetate—uterine cancer	0.00118	0.00215	CcSEcCtD
Alprostadil—Dry mouth—Medroxyprogesterone Acetate—uterine cancer	0.00117	0.00213	CcSEcCtD
Alprostadil—Flushing—Dactinomycin—uterine cancer	0.00117	0.00212	CcSEcCtD
Alprostadil—Vasodilation—Epirubicin—uterine cancer	0.00116	0.0021	CcSEcCtD
Alprostadil—Vasodilation procedure—Epirubicin—uterine cancer	0.00116	0.0021	CcSEcCtD
Alprostadil—Injection site pain—Doxorubicin—uterine cancer	0.00116	0.00209	CcSEcCtD
Alprostadil—Oedema—Medroxyprogesterone Acetate—uterine cancer	0.00115	0.00208	CcSEcCtD
Alprostadil—Infection—Medroxyprogesterone Acetate—uterine cancer	0.00114	0.00207	CcSEcCtD
Alprostadil—Shock—Medroxyprogesterone Acetate—uterine cancer	0.00113	0.00205	CcSEcCtD
Alprostadil—Thrombocytopenia—Medroxyprogesterone Acetate—uterine cancer	0.00113	0.00204	CcSEcCtD
Alprostadil—Tachycardia—Medroxyprogesterone Acetate—uterine cancer	0.00112	0.00203	CcSEcCtD
Alprostadil—Hyperbilirubinaemia—Epirubicin—uterine cancer	0.00112	0.00203	CcSEcCtD
Alprostadil—Dyspepsia—Progesterone—uterine cancer	0.00112	0.00202	CcSEcCtD
Alprostadil—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.00112	0.00202	CcSEcCtD
Alprostadil—Sweating increased—Etoposide—uterine cancer	0.00111	0.00202	CcSEcCtD
Alprostadil—Hyperhidrosis—Medroxyprogesterone Acetate—uterine cancer	0.00111	0.00201	CcSEcCtD
Alprostadil—Erythema—Dactinomycin—uterine cancer	0.0011	0.00199	CcSEcCtD
Alprostadil—Pain—Progesterone—uterine cancer	0.00108	0.00197	CcSEcCtD
Alprostadil—Hypotension—Medroxyprogesterone Acetate—uterine cancer	0.00107	0.00195	CcSEcCtD
Alprostadil—Vasodilation procedure—Doxorubicin—uterine cancer	0.00107	0.00195	CcSEcCtD
Alprostadil—Vasodilation—Doxorubicin—uterine cancer	0.00107	0.00195	CcSEcCtD
Alprostadil—Feeling abnormal—Progesterone—uterine cancer	0.00105	0.0019	CcSEcCtD
Alprostadil—Hyperbilirubinaemia—Doxorubicin—uterine cancer	0.00104	0.00188	CcSEcCtD
Alprostadil—Anaemia—Dactinomycin—uterine cancer	0.00102	0.00184	CcSEcCtD
Alprostadil—Injection site reaction—Epirubicin—uterine cancer	0.00101	0.00184	CcSEcCtD
Alprostadil—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.00101	0.00183	CcSEcCtD
Alprostadil—Acute coronary syndrome—Etoposide—uterine cancer	0.001	0.00182	CcSEcCtD
Alprostadil—Abdominal pain—Progesterone—uterine cancer	0.001	0.00182	CcSEcCtD
Alprostadil—Body temperature increased—Progesterone—uterine cancer	0.001	0.00182	CcSEcCtD
Alprostadil—Hyperkalaemia—Epirubicin—uterine cancer	0.001	0.00182	CcSEcCtD
Alprostadil—ABCC4—Fluoropyrimidine Activity—MTHFR—uterine cancer	0.001	0.0136	CbGpPWpGaD
Alprostadil—Renal failure—Etoposide—uterine cancer	0.001	0.00181	CcSEcCtD
Alprostadil—Myocardial infarction—Etoposide—uterine cancer	0.000997	0.00181	CcSEcCtD
Alprostadil—ABCC5—Defective B3GAT3 causes JDSSDHD—DCN—uterine cancer	0.000993	0.0135	CbGpPWpGaD
Alprostadil—Influenza like illness—Epirubicin—uterine cancer	0.00099	0.0018	CcSEcCtD
Alprostadil—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.000947	0.00172	CcSEcCtD
Alprostadil—Injection site reaction—Doxorubicin—uterine cancer	0.000938	0.0017	CcSEcCtD
Alprostadil—Cramps of lower extremities—Epirubicin—uterine cancer	0.000937	0.0017	CcSEcCtD
Alprostadil—Hyperkalaemia—Doxorubicin—uterine cancer	0.000927	0.00168	CcSEcCtD
Alprostadil—Discomfort—Dactinomycin—uterine cancer	0.000924	0.00168	CcSEcCtD
Alprostadil—Ecchymosis—Epirubicin—uterine cancer	0.000922	0.00167	CcSEcCtD
Alprostadil—Influenza like illness—Doxorubicin—uterine cancer	0.000916	0.00166	CcSEcCtD
Alprostadil—Asthenia—Progesterone—uterine cancer	0.00091	0.00165	CcSEcCtD
Alprostadil—Hypoaesthesia—Etoposide—uterine cancer	0.000909	0.00165	CcSEcCtD
Alprostadil—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000909	0.00165	CcSEcCtD
Alprostadil—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.000909	0.00165	CcSEcCtD
Alprostadil—Pruritus—Progesterone—uterine cancer	0.000897	0.00163	CcSEcCtD
Alprostadil—ABCC5—NRF2 pathway—NFE2L2—uterine cancer	0.000897	0.0122	CbGpPWpGaD
Alprostadil—Oedema—Dactinomycin—uterine cancer	0.000897	0.00163	CcSEcCtD
Alprostadil—Urethral disorder—Etoposide—uterine cancer	0.000895	0.00162	CcSEcCtD
Alprostadil—Infection—Dactinomycin—uterine cancer	0.000891	0.00161	CcSEcCtD
Alprostadil—Abnormal vision—Epirubicin—uterine cancer	0.000889	0.00161	CcSEcCtD
Alprostadil—Sepsis—Epirubicin—uterine cancer	0.000885	0.0016	CcSEcCtD
Alprostadil—Thrombocytopenia—Dactinomycin—uterine cancer	0.000878	0.00159	CcSEcCtD
Alprostadil—Diarrhoea—Progesterone—uterine cancer	0.000868	0.00157	CcSEcCtD
Alprostadil—Cramps of lower extremities—Doxorubicin—uterine cancer	0.000867	0.00157	CcSEcCtD
Alprostadil—ABCC5—NRF2 pathway—GPX3—uterine cancer	0.000855	0.0116	CbGpPWpGaD
Alprostadil—Ecchymosis—Doxorubicin—uterine cancer	0.000853	0.00155	CcSEcCtD
Alprostadil—Diabetes mellitus—Epirubicin—uterine cancer	0.000851	0.00154	CcSEcCtD
Alprostadil—Flushing—Etoposide—uterine cancer	0.000848	0.00154	CcSEcCtD
Alprostadil—Dizziness—Progesterone—uterine cancer	0.000839	0.00152	CcSEcCtD
Alprostadil—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000825	0.0015	CcSEcCtD
Alprostadil—Abnormal vision—Doxorubicin—uterine cancer	0.000823	0.00149	CcSEcCtD
Alprostadil—Sepsis—Doxorubicin—uterine cancer	0.000819	0.00148	CcSEcCtD
Alprostadil—Cardiac failure congestive—Epirubicin—uterine cancer	0.000816	0.00148	CcSEcCtD
Alprostadil—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000813	0.00147	CcSEcCtD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.000809	0.011	CbGpPWpGaD
Alprostadil—Rash—Progesterone—uterine cancer	0.0008	0.00145	CcSEcCtD
Alprostadil—Dermatitis—Progesterone—uterine cancer	0.000799	0.00145	CcSEcCtD
Alprostadil—Headache—Progesterone—uterine cancer	0.000795	0.00144	CcSEcCtD
Alprostadil—Diabetes mellitus—Doxorubicin—uterine cancer	0.000787	0.00143	CcSEcCtD
Alprostadil—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000786	0.00143	CcSEcCtD
Alprostadil—Back pain—Etoposide—uterine cancer	0.000769	0.00139	CcSEcCtD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.000767	0.0104	CbGpPWpGaD
Alprostadil—Pain—Dactinomycin—uterine cancer	0.000767	0.00139	CcSEcCtD
Alprostadil—Muscle spasms—Etoposide—uterine cancer	0.000764	0.00139	CcSEcCtD
Alprostadil—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.00076	0.00138	CcSEcCtD
Alprostadil—Hypoglycaemia—Epirubicin—uterine cancer	0.000758	0.00137	CcSEcCtD
Alprostadil—Lethargy—Epirubicin—uterine cancer	0.000755	0.00137	CcSEcCtD
Alprostadil—Cardiac failure congestive—Doxorubicin—uterine cancer	0.000755	0.00137	CcSEcCtD
Alprostadil—Nausea—Progesterone—uterine cancer	0.000753	0.00137	CcSEcCtD
Alprostadil—Pain in extremity—Epirubicin—uterine cancer	0.00074	0.00134	CcSEcCtD
Alprostadil—Feeling abnormal—Dactinomycin—uterine cancer	0.000739	0.00134	CcSEcCtD
Alprostadil—Anaemia—Etoposide—uterine cancer	0.000735	0.00133	CcSEcCtD
Alprostadil—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000725	0.00131	CcSEcCtD
Alprostadil—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000724	0.00131	CcSEcCtD
Alprostadil—Headache—Medroxyprogesterone Acetate—uterine cancer	0.00072	0.00131	CcSEcCtD
Alprostadil—Body temperature increased—Dactinomycin—uterine cancer	0.000709	0.00129	CcSEcCtD
Alprostadil—Abdominal pain—Dactinomycin—uterine cancer	0.000709	0.00129	CcSEcCtD
Alprostadil—Cardiac arrest—Epirubicin—uterine cancer	0.000704	0.00128	CcSEcCtD
Alprostadil—Hypoglycaemia—Doxorubicin—uterine cancer	0.000702	0.00127	CcSEcCtD
Alprostadil—Loss of consciousness—Etoposide—uterine cancer	0.000699	0.00127	CcSEcCtD
Alprostadil—Lethargy—Doxorubicin—uterine cancer	0.000699	0.00127	CcSEcCtD
Alprostadil—Cough—Etoposide—uterine cancer	0.000694	0.00126	CcSEcCtD
Alprostadil—Blood creatinine increased—Epirubicin—uterine cancer	0.000693	0.00126	CcSEcCtD
Alprostadil—Convulsion—Etoposide—uterine cancer	0.000689	0.00125	CcSEcCtD
Alprostadil—Hypertension—Etoposide—uterine cancer	0.000686	0.00124	CcSEcCtD
Alprostadil—Pain in extremity—Doxorubicin—uterine cancer	0.000685	0.00124	CcSEcCtD
Alprostadil—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000683	0.00124	CcSEcCtD
Alprostadil—Hypokalaemia—Epirubicin—uterine cancer	0.000674	0.00122	CcSEcCtD
Alprostadil—Discomfort—Etoposide—uterine cancer	0.000669	0.00121	CcSEcCtD
Alprostadil—Cardiac arrest—Doxorubicin—uterine cancer	0.000651	0.00118	CcSEcCtD
Alprostadil—Infection—Etoposide—uterine cancer	0.000645	0.00117	CcSEcCtD
Alprostadil—Asthenia—Dactinomycin—uterine cancer	0.000643	0.00117	CcSEcCtD
Alprostadil—Blood creatinine increased—Doxorubicin—uterine cancer	0.000642	0.00116	CcSEcCtD
Alprostadil—Influenza—Epirubicin—uterine cancer	0.00064	0.00116	CcSEcCtD
Alprostadil—Thrombocytopenia—Etoposide—uterine cancer	0.000635	0.00115	CcSEcCtD
Alprostadil—Tachycardia—Etoposide—uterine cancer	0.000633	0.00115	CcSEcCtD
Alprostadil—Skin disorder—Etoposide—uterine cancer	0.00063	0.00114	CcSEcCtD
Alprostadil—Hyperhidrosis—Etoposide—uterine cancer	0.000627	0.00114	CcSEcCtD
Alprostadil—Hypokalaemia—Doxorubicin—uterine cancer	0.000623	0.00113	CcSEcCtD
Alprostadil—ABCC4—NRF2 pathway—NFE2L2—uterine cancer	0.000622	0.00846	CbGpPWpGaD
Alprostadil—Bronchitis—Epirubicin—uterine cancer	0.000615	0.00112	CcSEcCtD
Alprostadil—Diarrhoea—Dactinomycin—uterine cancer	0.000613	0.00111	CcSEcCtD
Alprostadil—Hypotension—Etoposide—uterine cancer	0.000606	0.0011	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000594	0.00108	CcSEcCtD
Alprostadil—ABCC4—NRF2 pathway—GPX3—uterine cancer	0.000593	0.00807	CbGpPWpGaD
Alprostadil—Influenza—Doxorubicin—uterine cancer	0.000592	0.00107	CcSEcCtD
Alprostadil—Pollakiuria—Epirubicin—uterine cancer	0.000591	0.00107	CcSEcCtD
Alprostadil—Hyperglycaemia—Epirubicin—uterine cancer	0.000577	0.00105	CcSEcCtD
Alprostadil—Bronchitis—Doxorubicin—uterine cancer	0.000569	0.00103	CcSEcCtD
Alprostadil—Rash—Dactinomycin—uterine cancer	0.000565	0.00102	CcSEcCtD
Alprostadil—Renal failure—Epirubicin—uterine cancer	0.000561	0.00102	CcSEcCtD
Alprostadil—Pain—Etoposide—uterine cancer	0.000555	0.00101	CcSEcCtD
Alprostadil—Urinary tract infection—Epirubicin—uterine cancer	0.000554	0.00101	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.00055	0.000997	CcSEcCtD
Alprostadil—ABCC5—Fluoropyrimidine Activity—TP53—uterine cancer	0.000548	0.00746	CbGpPWpGaD
Alprostadil—Pollakiuria—Doxorubicin—uterine cancer	0.000547	0.000991	CcSEcCtD
Alprostadil—Haematuria—Epirubicin—uterine cancer	0.000544	0.000986	CcSEcCtD
Alprostadil—Sinusitis—Epirubicin—uterine cancer	0.000535	0.00097	CcSEcCtD
Alprostadil—Feeling abnormal—Etoposide—uterine cancer	0.000535	0.00097	CcSEcCtD
Alprostadil—Hyperglycaemia—Doxorubicin—uterine cancer	0.000534	0.000968	CcSEcCtD
Alprostadil—ABCC5—Carbohydrate metabolism—DCN—uterine cancer	0.000533	0.00725	CbGpPWpGaD
Alprostadil—Nausea—Dactinomycin—uterine cancer	0.000533	0.000966	CcSEcCtD
Alprostadil—Bradycardia—Epirubicin—uterine cancer	0.000521	0.000945	CcSEcCtD
Alprostadil—Renal failure—Doxorubicin—uterine cancer	0.000519	0.000941	CcSEcCtD
Alprostadil—Haemoglobin—Epirubicin—uterine cancer	0.000515	0.000933	CcSEcCtD
Alprostadil—Rhinitis—Epirubicin—uterine cancer	0.000513	0.000931	CcSEcCtD
Alprostadil—Abdominal pain—Etoposide—uterine cancer	0.000513	0.00093	CcSEcCtD
Alprostadil—Body temperature increased—Etoposide—uterine cancer	0.000513	0.00093	CcSEcCtD
Alprostadil—Urinary tract infection—Doxorubicin—uterine cancer	0.000513	0.00093	CcSEcCtD
Alprostadil—Haemorrhage—Epirubicin—uterine cancer	0.000512	0.000928	CcSEcCtD
Alprostadil—Hypoaesthesia—Epirubicin—uterine cancer	0.000509	0.000924	CcSEcCtD
Alprostadil—Pharyngitis—Epirubicin—uterine cancer	0.000508	0.000921	CcSEcCtD
Alprostadil—Haematuria—Doxorubicin—uterine cancer	0.000503	0.000912	CcSEcCtD
Alprostadil—Urethral disorder—Epirubicin—uterine cancer	0.000502	0.00091	CcSEcCtD
Alprostadil—Sinusitis—Doxorubicin—uterine cancer	0.000495	0.000898	CcSEcCtD
Alprostadil—Visual impairment—Epirubicin—uterine cancer	0.000493	0.000895	CcSEcCtD
Alprostadil—Bradycardia—Doxorubicin—uterine cancer	0.000482	0.000874	CcSEcCtD
Alprostadil—Haemoglobin—Doxorubicin—uterine cancer	0.000476	0.000863	CcSEcCtD
Alprostadil—Flushing—Epirubicin—uterine cancer	0.000475	0.000862	CcSEcCtD
Alprostadil—Rhinitis—Doxorubicin—uterine cancer	0.000475	0.000861	CcSEcCtD
Alprostadil—Haemorrhage—Doxorubicin—uterine cancer	0.000474	0.000859	CcSEcCtD
Alprostadil—Hypoaesthesia—Doxorubicin—uterine cancer	0.000471	0.000855	CcSEcCtD
Alprostadil—Pharyngitis—Doxorubicin—uterine cancer	0.00047	0.000852	CcSEcCtD
Alprostadil—Asthenia—Etoposide—uterine cancer	0.000466	0.000844	CcSEcCtD
Alprostadil—Urethral disorder—Doxorubicin—uterine cancer	0.000464	0.000842	CcSEcCtD
Alprostadil—Pruritus—Etoposide—uterine cancer	0.000459	0.000832	CcSEcCtD
Alprostadil—Visual impairment—Doxorubicin—uterine cancer	0.000457	0.000828	CcSEcCtD
Alprostadil—Erythema—Epirubicin—uterine cancer	0.000446	0.000808	CcSEcCtD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.000445	0.00605	CbGpPWpGaD
Alprostadil—Diarrhoea—Etoposide—uterine cancer	0.000444	0.000805	CcSEcCtD
Alprostadil—Flushing—Doxorubicin—uterine cancer	0.00044	0.000797	CcSEcCtD
Alprostadil—Nervousness—Epirubicin—uterine cancer	0.000433	0.000785	CcSEcCtD
Alprostadil—Back pain—Epirubicin—uterine cancer	0.000431	0.000782	CcSEcCtD
Alprostadil—Dizziness—Etoposide—uterine cancer	0.000429	0.000778	CcSEcCtD
Alprostadil—Muscle spasms—Epirubicin—uterine cancer	0.000428	0.000777	CcSEcCtD
Alprostadil—ABCC5—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.000425	0.00579	CbGpPWpGaD
Alprostadil—Erythema—Doxorubicin—uterine cancer	0.000412	0.000748	CcSEcCtD
Alprostadil—Anaemia—Epirubicin—uterine cancer	0.000412	0.000747	CcSEcCtD
Alprostadil—Rash—Etoposide—uterine cancer	0.000409	0.000742	CcSEcCtD
Alprostadil—Dermatitis—Etoposide—uterine cancer	0.000409	0.000741	CcSEcCtD
Alprostadil—Headache—Etoposide—uterine cancer	0.000407	0.000737	CcSEcCtD
Alprostadil—Nervousness—Doxorubicin—uterine cancer	0.000401	0.000726	CcSEcCtD
Alprostadil—Syncope—Epirubicin—uterine cancer	0.0004	0.000725	CcSEcCtD
Alprostadil—Back pain—Doxorubicin—uterine cancer	0.000399	0.000723	CcSEcCtD
Alprostadil—Muscle spasms—Doxorubicin—uterine cancer	0.000396	0.000719	CcSEcCtD
Alprostadil—Loss of consciousness—Epirubicin—uterine cancer	0.000392	0.00071	CcSEcCtD
Alprostadil—Cough—Epirubicin—uterine cancer	0.000389	0.000705	CcSEcCtD
Alprostadil—Convulsion—Epirubicin—uterine cancer	0.000386	0.0007	CcSEcCtD
Alprostadil—Nausea—Etoposide—uterine cancer	0.000385	0.000699	CcSEcCtD
Alprostadil—Hypertension—Epirubicin—uterine cancer	0.000385	0.000698	CcSEcCtD
Alprostadil—Anaemia—Doxorubicin—uterine cancer	0.000381	0.000691	CcSEcCtD
Alprostadil—ABCC4—Fluoropyrimidine Activity—TP53—uterine cancer	0.00038	0.00517	CbGpPWpGaD
Alprostadil—Discomfort—Epirubicin—uterine cancer	0.000375	0.00068	CcSEcCtD
Alprostadil—Dry mouth—Epirubicin—uterine cancer	0.000371	0.000673	CcSEcCtD
Alprostadil—Syncope—Doxorubicin—uterine cancer	0.00037	0.000671	CcSEcCtD
Alprostadil—Oedema—Epirubicin—uterine cancer	0.000364	0.000659	CcSEcCtD
Alprostadil—Loss of consciousness—Doxorubicin—uterine cancer	0.000362	0.000657	CcSEcCtD
Alprostadil—Infection—Epirubicin—uterine cancer	0.000361	0.000655	CcSEcCtD
Alprostadil—Cough—Doxorubicin—uterine cancer	0.00036	0.000652	CcSEcCtD
Alprostadil—Shock—Epirubicin—uterine cancer	0.000358	0.000649	CcSEcCtD
Alprostadil—Convulsion—Doxorubicin—uterine cancer	0.000357	0.000648	CcSEcCtD
Alprostadil—Thrombocytopenia—Epirubicin—uterine cancer	0.000356	0.000646	CcSEcCtD
Alprostadil—Hypertension—Doxorubicin—uterine cancer	0.000356	0.000646	CcSEcCtD
Alprostadil—Tachycardia—Epirubicin—uterine cancer	0.000355	0.000644	CcSEcCtD
Alprostadil—Skin disorder—Epirubicin—uterine cancer	0.000353	0.000641	CcSEcCtD
Alprostadil—PTGIR—Thromboxane A2 receptor signaling—AKT1—uterine cancer	0.000352	0.0048	CbGpPWpGaD
Alprostadil—Hyperhidrosis—Epirubicin—uterine cancer	0.000352	0.000638	CcSEcCtD
Alprostadil—Discomfort—Doxorubicin—uterine cancer	0.000347	0.000629	CcSEcCtD
Alprostadil—Dry mouth—Doxorubicin—uterine cancer	0.000343	0.000623	CcSEcCtD
Alprostadil—Hypotension—Epirubicin—uterine cancer	0.00034	0.000616	CcSEcCtD
Alprostadil—Oedema—Doxorubicin—uterine cancer	0.000337	0.00061	CcSEcCtD
Alprostadil—Infection—Doxorubicin—uterine cancer	0.000334	0.000606	CcSEcCtD
Alprostadil—Shock—Doxorubicin—uterine cancer	0.000331	0.0006	CcSEcCtD
Alprostadil—ABCC4—Ectoderm Differentiation—FGFR2—uterine cancer	0.000331	0.0045	CbGpPWpGaD
Alprostadil—Thrombocytopenia—Doxorubicin—uterine cancer	0.00033	0.000597	CcSEcCtD
Alprostadil—Tachycardia—Doxorubicin—uterine cancer	0.000328	0.000596	CcSEcCtD
Alprostadil—Skin disorder—Doxorubicin—uterine cancer	0.000327	0.000593	CcSEcCtD
Alprostadil—Hyperhidrosis—Doxorubicin—uterine cancer	0.000325	0.00059	CcSEcCtD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	0.000321	0.00437	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—IRF1—uterine cancer	0.000321	0.00437	CbGpPWpGaD
Alprostadil—Dyspepsia—Epirubicin—uterine cancer	0.00032	0.000581	CcSEcCtD
Alprostadil—Hypotension—Doxorubicin—uterine cancer	0.000314	0.00057	CcSEcCtD
Alprostadil—Pain—Epirubicin—uterine cancer	0.000311	0.000564	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—AKR1B10—uterine cancer	0.000308	0.0042	CbGpPWpGaD
Alprostadil—Feeling abnormal—Epirubicin—uterine cancer	0.0003	0.000543	CcSEcCtD
Alprostadil—Dyspepsia—Doxorubicin—uterine cancer	0.000296	0.000537	CcSEcCtD
Alprostadil—ABCC4—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.000295	0.00401	CbGpPWpGaD
Alprostadil—Pain—Doxorubicin—uterine cancer	0.000288	0.000522	CcSEcCtD
Alprostadil—Abdominal pain—Epirubicin—uterine cancer	0.000288	0.000521	CcSEcCtD
Alprostadil—Body temperature increased—Epirubicin—uterine cancer	0.000288	0.000521	CcSEcCtD
Alprostadil—Feeling abnormal—Doxorubicin—uterine cancer	0.000277	0.000503	CcSEcCtD
Alprostadil—ABCC5—Metabolism—SRD5A2—uterine cancer	0.000275	0.00375	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—NDUFB11—uterine cancer	0.000275	0.00375	CbGpPWpGaD
Alprostadil—Body temperature increased—Doxorubicin—uterine cancer	0.000266	0.000482	CcSEcCtD
Alprostadil—Abdominal pain—Doxorubicin—uterine cancer	0.000266	0.000482	CcSEcCtD
Alprostadil—Asthenia—Epirubicin—uterine cancer	0.000261	0.000473	CcSEcCtD
Alprostadil—Pruritus—Epirubicin—uterine cancer	0.000257	0.000467	CcSEcCtD
Alprostadil—ABCC5—Disease—AKR1B10—uterine cancer	0.000256	0.00348	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—RNF43—uterine cancer	0.000255	0.00348	CbGpPWpGaD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	0.000254	0.00346	CbGpPWpGaD
Alprostadil—ABCC4—Ectoderm Differentiation—CCL2—uterine cancer	0.000249	0.00339	CbGpPWpGaD
Alprostadil—Diarrhoea—Epirubicin—uterine cancer	0.000249	0.000451	CcSEcCtD
Alprostadil—ABCC4—Platelet degranulation—VEGFA—uterine cancer	0.000247	0.00337	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—CCL2—uterine cancer	0.000245	0.00333	CbGpPWpGaD
Alprostadil—Asthenia—Doxorubicin—uterine cancer	0.000241	0.000438	CcSEcCtD
Alprostadil—Dizziness—Epirubicin—uterine cancer	0.000241	0.000436	CcSEcCtD
Alprostadil—Pruritus—Doxorubicin—uterine cancer	0.000238	0.000432	CcSEcCtD
Alprostadil—ABCC4—Response to elevated platelet cytosolic Ca2+—VEGFA—uterine cancer	0.000236	0.00321	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—INHBA—uterine cancer	0.000234	0.00318	CbGpPWpGaD
Alprostadil—Diarrhoea—Doxorubicin—uterine cancer	0.00023	0.000418	CcSEcCtD
Alprostadil—Rash—Epirubicin—uterine cancer	0.000229	0.000416	CcSEcCtD
Alprostadil—Dermatitis—Epirubicin—uterine cancer	0.000229	0.000415	CcSEcCtD
Alprostadil—Headache—Epirubicin—uterine cancer	0.000228	0.000413	CcSEcCtD
Alprostadil—Dizziness—Doxorubicin—uterine cancer	0.000223	0.000404	CcSEcCtD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	0.000217	0.00295	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	0.000217	0.00295	CbGpPWpGaD
Alprostadil—Nausea—Epirubicin—uterine cancer	0.000216	0.000392	CcSEcCtD
Alprostadil—Rash—Doxorubicin—uterine cancer	0.000212	0.000385	CcSEcCtD
Alprostadil—Dermatitis—Doxorubicin—uterine cancer	0.000212	0.000384	CcSEcCtD
Alprostadil—ABCC5—Disease—RNF43—uterine cancer	0.000212	0.00288	CbGpPWpGaD
Alprostadil—Headache—Doxorubicin—uterine cancer	0.000211	0.000382	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—AKR1C1—uterine cancer	0.00021	0.00286	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—AKR1B10—uterine cancer	0.000208	0.00283	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—AKR1B10—uterine cancer	0.000208	0.00283	CbGpPWpGaD
Alprostadil—Nausea—Doxorubicin—uterine cancer	0.0002	0.000362	CcSEcCtD
Alprostadil—ABCC5—Metabolism—AKR1B1—uterine cancer	0.000199	0.00271	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—STAR—uterine cancer	0.000199	0.00271	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—CXCL8—uterine cancer	0.000194	0.00263	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—IRF1—uterine cancer	0.000191	0.0026	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—uterine cancer	0.000186	0.00253	CbGpPWpGaD
Alprostadil—ABCC4—Ectoderm Differentiation—CTNNB1—uterine cancer	0.000182	0.00247	CbGpPWpGaD
Alprostadil—ABCC5—Disease—AKR1C1—uterine cancer	0.000175	0.00237	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—RNF43—uterine cancer	0.000173	0.00235	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—RNF43—uterine cancer	0.000173	0.00235	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	0.000172	0.00234	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	0.000172	0.00234	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—CCL2—uterine cancer	0.000165	0.00225	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—CCL2—uterine cancer	0.000165	0.00225	CbGpPWpGaD
Alprostadil—PTGER1—G alpha (q) signalling events—PIK3CA—uterine cancer	0.000164	0.00224	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—AKR1C3—uterine cancer	0.000162	0.0022	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—uterine cancer	0.00016	0.00218	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—INHBA—uterine cancer	0.000158	0.00215	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—INHBA—uterine cancer	0.000158	0.00215	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PGR—uterine cancer	0.000158	0.00215	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—POLD1—uterine cancer	0.000156	0.00213	CbGpPWpGaD
Alprostadil—ABCC5—Disease—DCN—uterine cancer	0.000151	0.00205	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—YWHAE—uterine cancer	0.000151	0.00205	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—uterine cancer	0.000147	0.002	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—AKR1C1—uterine cancer	0.000146	0.00199	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—FBXW7—uterine cancer	0.000144	0.00196	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—AKR1C1—uterine cancer	0.000142	0.00193	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—AKR1C1—uterine cancer	0.000142	0.00193	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—uterine cancer	0.000136	0.00185	CbGpPWpGaD
Alprostadil—ABCC5—Disease—AKR1C3—uterine cancer	0.000134	0.00183	CbGpPWpGaD
Alprostadil—ABCC5—Disease—HMGA1—uterine cancer	0.000131	0.00178	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—CXCL8—uterine cancer	0.000131	0.00178	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—CXCL8—uterine cancer	0.000131	0.00178	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—RRM2—uterine cancer	0.00013	0.00177	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—DCN—uterine cancer	0.000126	0.00172	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—STK11—uterine cancer	0.000126	0.00172	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—CCL2—uterine cancer	0.000126	0.00171	CbGpPWpGaD
Alprostadil—ABCC5—Disease—FBXW7—uterine cancer	0.00012	0.00163	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CYP11A1—uterine cancer	0.000119	0.00162	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—SOCS3—uterine cancer	0.000118	0.00161	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CDKN2B—uterine cancer	0.000113	0.00154	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—AKR1C3—uterine cancer	0.000113	0.00153	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IGF1R—uterine cancer	0.00011	0.00149	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—VEGFA—uterine cancer	0.00011	0.00149	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—AKR1C3—uterine cancer	0.000109	0.00149	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—AKR1C3—uterine cancer	0.000109	0.00149	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—CXCL8—uterine cancer	0.000109	0.00149	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PGR—uterine cancer	0.000107	0.00145	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PGR—uterine cancer	0.000107	0.00145	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—SMAD3—uterine cancer	0.000103	0.00141	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—YWHAE—uterine cancer	0.000102	0.00138	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—YWHAE—uterine cancer	0.000102	0.00138	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—EP300—uterine cancer	0.0001	0.00136	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—CXCL8—uterine cancer	9.93e-05	0.00135	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—FGFR2—uterine cancer	9.85e-05	0.00134	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—FBXW7—uterine cancer	9.75e-05	0.00133	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—FBXW7—uterine cancer	9.75e-05	0.00133	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—VEGFA—uterine cancer	9.49e-05	0.00129	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CDKN2B—uterine cancer	9.38e-05	0.00128	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—NRAS—uterine cancer	9.38e-05	0.00128	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—STK11—uterine cancer	8.77e-05	0.00119	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CYP19A1—uterine cancer	8.77e-05	0.00119	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—PIK3CA—uterine cancer	8.57e-05	0.00117	CbGpPWpGaD
Alprostadil—ABCC5—Disease—SMAD3—uterine cancer	8.57e-05	0.00117	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—STK11—uterine cancer	8.52e-05	0.00116	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—STK11—uterine cancer	8.52e-05	0.00116	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—CCL2—uterine cancer	8.48e-05	0.00115	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—CCL2—uterine cancer	8.48e-05	0.00115	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—ESR1—uterine cancer	8.43e-05	0.00115	CbGpPWpGaD
Alprostadil—ABCC5—Disease—FGFR2—uterine cancer	8.17e-05	0.00111	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—KRAS—uterine cancer	8.07e-05	0.0011	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SOCS3—uterine cancer	7.98e-05	0.00109	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—SOCS3—uterine cancer	7.98e-05	0.00109	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—NRAS—uterine cancer	7.97e-05	0.00108	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MTHFR—uterine cancer	7.87e-05	0.00107	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CDKN2B—uterine cancer	7.64e-05	0.00104	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CDKN2B—uterine cancer	7.64e-05	0.00104	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IGF1R—uterine cancer	7.42e-05	0.00101	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CCL2—uterine cancer	7.42e-05	0.00101	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IGF1R—uterine cancer	7.42e-05	0.00101	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—PIK3CA—uterine cancer	7.41e-05	0.00101	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—CXCL8—uterine cancer	7.39e-05	0.00101	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—CXCL8—uterine cancer	7.39e-05	0.00101	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—TP53—uterine cancer	7.17e-05	0.000976	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—AKT1—uterine cancer	7e-05	0.000953	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—SMAD3—uterine cancer	6.98e-05	0.000949	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SMAD3—uterine cancer	6.98e-05	0.000949	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—PIK3CA—uterine cancer	6.94e-05	0.000944	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—HRAS—uterine cancer	6.86e-05	0.000934	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—KRAS—uterine cancer	6.86e-05	0.000933	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—CXCL8—uterine cancer	6.71e-05	0.000913	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—CXCL8—uterine cancer	6.71e-05	0.000913	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—FGFR2—uterine cancer	6.65e-05	0.000905	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—FGFR2—uterine cancer	6.65e-05	0.000905	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—MTHFR—uterine cancer	6.59e-05	0.000896	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—PIK3CA—uterine cancer	6.3e-05	0.000857	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—ERBB2—uterine cancer	6.19e-05	0.000842	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—AKT1—uterine cancer	6.06e-05	0.000824	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—EP300—uterine cancer	5.97e-05	0.000813	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CXCL8—uterine cancer	5.87e-05	0.000798	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—HRAS—uterine cancer	5.83e-05	0.000793	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CDKN1B—uterine cancer	5.73e-05	0.00078	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ESR1—uterine cancer	5.69e-05	0.000775	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ESR1—uterine cancer	5.69e-05	0.000775	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—AKT1—uterine cancer	5.67e-05	0.000771	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—VEGFA—uterine cancer	5.66e-05	0.00077	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—NRAS—uterine cancer	5.59e-05	0.000761	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CTNNB1—uterine cancer	5.41e-05	0.000736	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—NRAS—uterine cancer	5.38e-05	0.000732	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—NRAS—uterine cancer	5.38e-05	0.000732	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PTEN—uterine cancer	5.28e-05	0.000718	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—AKT1—uterine cancer	5.15e-05	0.0007	CbGpPWpGaD
Alprostadil—ABCC5—Disease—ERBB2—uterine cancer	5.13e-05	0.000698	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—EP300—uterine cancer	5.03e-05	0.000685	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CCL2—uterine cancer	5.01e-05	0.000682	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CCL2—uterine cancer	5.01e-05	0.000682	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—KRAS—uterine cancer	4.81e-05	0.000655	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—VEGFA—uterine cancer	4.76e-05	0.000648	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CDKN1B—uterine cancer	4.75e-05	0.000647	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—NRAS—uterine cancer	4.71e-05	0.00064	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—PIK3CA—uterine cancer	4.69e-05	0.000638	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—PIK3CA—uterine cancer	4.69e-05	0.000638	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—KRAS—uterine cancer	4.63e-05	0.00063	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—KRAS—uterine cancer	4.63e-05	0.00063	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CTNNB1—uterine cancer	4.49e-05	0.000611	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PIK3CA—uterine cancer	4.42e-05	0.000601	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PTEN—uterine cancer	4.38e-05	0.000595	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—TP53—uterine cancer	4.28e-05	0.000582	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PIK3CA—uterine cancer	4.26e-05	0.000579	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PIK3CA—uterine cancer	4.26e-05	0.000579	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ERBB2—uterine cancer	4.18e-05	0.000569	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ERBB2—uterine cancer	4.18e-05	0.000569	CbGpPWpGaD
Alprostadil—ABCC5—Disease—EP300—uterine cancer	4.17e-05	0.000568	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—HRAS—uterine cancer	4.09e-05	0.000556	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—KRAS—uterine cancer	4.05e-05	0.000551	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CXCL8—uterine cancer	3.96e-05	0.000539	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CXCL8—uterine cancer	3.96e-05	0.000539	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—HRAS—uterine cancer	3.94e-05	0.000536	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—HRAS—uterine cancer	3.94e-05	0.000536	CbGpPWpGaD
Alprostadil—ABCC5—Disease—NRAS—uterine cancer	3.9e-05	0.000531	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CDKN1B—uterine cancer	3.87e-05	0.000527	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CDKN1B—uterine cancer	3.87e-05	0.000527	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—AKT1—uterine cancer	3.83e-05	0.000521	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—AKT1—uterine cancer	3.83e-05	0.000521	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PIK3CA—uterine cancer	3.72e-05	0.000506	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PTEN—uterine cancer	3.66e-05	0.000499	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CTNNB1—uterine cancer	3.66e-05	0.000497	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CTNNB1—uterine cancer	3.66e-05	0.000497	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—AKT1—uterine cancer	3.61e-05	0.000491	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TP53—uterine cancer	3.6e-05	0.00049	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PTEN—uterine cancer	3.56e-05	0.000485	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PTEN—uterine cancer	3.56e-05	0.000485	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—EP300—uterine cancer	3.49e-05	0.000476	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—AKT1—uterine cancer	3.48e-05	0.000473	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—AKT1—uterine cancer	3.48e-05	0.000473	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—HRAS—uterine cancer	3.44e-05	0.000469	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—EP300—uterine cancer	3.4e-05	0.000462	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—EP300—uterine cancer	3.4e-05	0.000462	CbGpPWpGaD
Alprostadil—ABCC5—Disease—KRAS—uterine cancer	3.36e-05	0.000457	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—VEGFA—uterine cancer	3.22e-05	0.000438	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—VEGFA—uterine cancer	3.22e-05	0.000438	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NRAS—uterine cancer	3.18e-05	0.000433	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NRAS—uterine cancer	3.18e-05	0.000433	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PIK3CA—uterine cancer	3.09e-05	0.00042	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—AKT1—uterine cancer	3.04e-05	0.000414	CbGpPWpGaD
Alprostadil—ABCC5—Disease—HRAS—uterine cancer	2.86e-05	0.000389	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—KRAS—uterine cancer	2.74e-05	0.000372	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—KRAS—uterine cancer	2.74e-05	0.000372	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PIK3CA—uterine cancer	2.59e-05	0.000352	CbGpPWpGaD
Alprostadil—ABCC5—Disease—AKT1—uterine cancer	2.52e-05	0.000343	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PIK3CA—uterine cancer	2.51e-05	0.000342	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PIK3CA—uterine cancer	2.51e-05	0.000342	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TP53—uterine cancer	2.43e-05	0.000331	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TP53—uterine cancer	2.43e-05	0.000331	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—HRAS—uterine cancer	2.33e-05	0.000316	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—HRAS—uterine cancer	2.33e-05	0.000316	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—AKT1—uterine cancer	2.11e-05	0.000287	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—AKT1—uterine cancer	2.05e-05	0.000279	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—AKT1—uterine cancer	2.05e-05	0.000279	CbGpPWpGaD
